Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons

Diego Centonze, Paolo Calabresi, Antonio Pisani, Silvia Marinelli, Girolama Alessandra Marfia, Giorgio Bernardi

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Striatal spiny neurons are selectively vulnerable in Huntington's disease (HD). No effective treatment is available to limit neuronal death in this pathological condition. In an experimental model of HD, a beneficial effect has recently been reported by the neuroprotective agent riluzole. We performed intracellular recordings in order to characterize the electrophysiological effects of this compound on striatal spiny neurons. Riluzole (0.1-100 μM) affected neither the resting membrane potential nor the input resistance/membrane conductance of the recorded cells. Bath application of this pharmacological agent produced a dose-dependent reduction of the number of spikes evoked by long-lasting depolarizing pulses. The EC50 value for this effect was 0.5 μM. Low doses of riluzole selectively reduced the firing frequency in the last part of the depolarizing pulse suggesting a use-dependent action at low concentrations of this compound. Riluzole produced a dose-dependent reduction of the amplitude of the corticostriatal glutamatergic excitatory post-synaptic potentials (EPSPs) with an extrapolated EC50 value of 6 μM. This effect was reversible and maximal at a concentration of 100 μM. Paired-pulse facilitation (PPF) was not affected by riluzole suggesting that the reduction of excitatory transmission was not only caused by a decrease of presynaptic release. Accordingly, riluzole also reduced the amplitude of membrane depolarization induced by exogenous glutamate. The modulatory action of riluzole on the activity of striatal spiny neurons might support the use of this drug in experimental models of excitotoxicity and in the neurodegenerative disorders involving the striatum. Copyright (C) 1998 Elsevier Science Ltd.

Original languageEnglish
Pages (from-to)1063-1070
Number of pages8
JournalNeuropharmacology
Volume37
Issue number8
DOIs
Publication statusPublished - Aug 1998

Fingerprint

Riluzole
Corpus Striatum
Electrophysiology
Neuroprotective Agents
Neurons
Huntington Disease
Theoretical Models
Synaptic Potentials
Membranes
Baths
Neurodegenerative Diseases
Membrane Potentials
Glutamic Acid
Pharmacology

Keywords

  • Excitatory amino acids
  • Huntington disease
  • Intracellular recordings
  • Striatum
  • Synaptic transmission

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Drug Discovery
  • Pharmacology

Cite this

Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. / Centonze, Diego; Calabresi, Paolo; Pisani, Antonio; Marinelli, Silvia; Marfia, Girolama Alessandra; Bernardi, Giorgio.

In: Neuropharmacology, Vol. 37, No. 8, 08.1998, p. 1063-1070.

Research output: Contribution to journalArticle

Centonze, Diego ; Calabresi, Paolo ; Pisani, Antonio ; Marinelli, Silvia ; Marfia, Girolama Alessandra ; Bernardi, Giorgio. / Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. In: Neuropharmacology. 1998 ; Vol. 37, No. 8. pp. 1063-1070.
@article{fac2a0288dc844618dd1d5672fb1c9e3,
title = "Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons",
abstract = "Striatal spiny neurons are selectively vulnerable in Huntington's disease (HD). No effective treatment is available to limit neuronal death in this pathological condition. In an experimental model of HD, a beneficial effect has recently been reported by the neuroprotective agent riluzole. We performed intracellular recordings in order to characterize the electrophysiological effects of this compound on striatal spiny neurons. Riluzole (0.1-100 μM) affected neither the resting membrane potential nor the input resistance/membrane conductance of the recorded cells. Bath application of this pharmacological agent produced a dose-dependent reduction of the number of spikes evoked by long-lasting depolarizing pulses. The EC50 value for this effect was 0.5 μM. Low doses of riluzole selectively reduced the firing frequency in the last part of the depolarizing pulse suggesting a use-dependent action at low concentrations of this compound. Riluzole produced a dose-dependent reduction of the amplitude of the corticostriatal glutamatergic excitatory post-synaptic potentials (EPSPs) with an extrapolated EC50 value of 6 μM. This effect was reversible and maximal at a concentration of 100 μM. Paired-pulse facilitation (PPF) was not affected by riluzole suggesting that the reduction of excitatory transmission was not only caused by a decrease of presynaptic release. Accordingly, riluzole also reduced the amplitude of membrane depolarization induced by exogenous glutamate. The modulatory action of riluzole on the activity of striatal spiny neurons might support the use of this drug in experimental models of excitotoxicity and in the neurodegenerative disorders involving the striatum. Copyright (C) 1998 Elsevier Science Ltd.",
keywords = "Excitatory amino acids, Huntington disease, Intracellular recordings, Striatum, Synaptic transmission",
author = "Diego Centonze and Paolo Calabresi and Antonio Pisani and Silvia Marinelli and Marfia, {Girolama Alessandra} and Giorgio Bernardi",
year = "1998",
month = "8",
doi = "10.1016/S0028-3908(98)00081-1",
language = "English",
volume = "37",
pages = "1063--1070",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons

AU - Centonze, Diego

AU - Calabresi, Paolo

AU - Pisani, Antonio

AU - Marinelli, Silvia

AU - Marfia, Girolama Alessandra

AU - Bernardi, Giorgio

PY - 1998/8

Y1 - 1998/8

N2 - Striatal spiny neurons are selectively vulnerable in Huntington's disease (HD). No effective treatment is available to limit neuronal death in this pathological condition. In an experimental model of HD, a beneficial effect has recently been reported by the neuroprotective agent riluzole. We performed intracellular recordings in order to characterize the electrophysiological effects of this compound on striatal spiny neurons. Riluzole (0.1-100 μM) affected neither the resting membrane potential nor the input resistance/membrane conductance of the recorded cells. Bath application of this pharmacological agent produced a dose-dependent reduction of the number of spikes evoked by long-lasting depolarizing pulses. The EC50 value for this effect was 0.5 μM. Low doses of riluzole selectively reduced the firing frequency in the last part of the depolarizing pulse suggesting a use-dependent action at low concentrations of this compound. Riluzole produced a dose-dependent reduction of the amplitude of the corticostriatal glutamatergic excitatory post-synaptic potentials (EPSPs) with an extrapolated EC50 value of 6 μM. This effect was reversible and maximal at a concentration of 100 μM. Paired-pulse facilitation (PPF) was not affected by riluzole suggesting that the reduction of excitatory transmission was not only caused by a decrease of presynaptic release. Accordingly, riluzole also reduced the amplitude of membrane depolarization induced by exogenous glutamate. The modulatory action of riluzole on the activity of striatal spiny neurons might support the use of this drug in experimental models of excitotoxicity and in the neurodegenerative disorders involving the striatum. Copyright (C) 1998 Elsevier Science Ltd.

AB - Striatal spiny neurons are selectively vulnerable in Huntington's disease (HD). No effective treatment is available to limit neuronal death in this pathological condition. In an experimental model of HD, a beneficial effect has recently been reported by the neuroprotective agent riluzole. We performed intracellular recordings in order to characterize the electrophysiological effects of this compound on striatal spiny neurons. Riluzole (0.1-100 μM) affected neither the resting membrane potential nor the input resistance/membrane conductance of the recorded cells. Bath application of this pharmacological agent produced a dose-dependent reduction of the number of spikes evoked by long-lasting depolarizing pulses. The EC50 value for this effect was 0.5 μM. Low doses of riluzole selectively reduced the firing frequency in the last part of the depolarizing pulse suggesting a use-dependent action at low concentrations of this compound. Riluzole produced a dose-dependent reduction of the amplitude of the corticostriatal glutamatergic excitatory post-synaptic potentials (EPSPs) with an extrapolated EC50 value of 6 μM. This effect was reversible and maximal at a concentration of 100 μM. Paired-pulse facilitation (PPF) was not affected by riluzole suggesting that the reduction of excitatory transmission was not only caused by a decrease of presynaptic release. Accordingly, riluzole also reduced the amplitude of membrane depolarization induced by exogenous glutamate. The modulatory action of riluzole on the activity of striatal spiny neurons might support the use of this drug in experimental models of excitotoxicity and in the neurodegenerative disorders involving the striatum. Copyright (C) 1998 Elsevier Science Ltd.

KW - Excitatory amino acids

KW - Huntington disease

KW - Intracellular recordings

KW - Striatum

KW - Synaptic transmission

UR - http://www.scopus.com/inward/record.url?scp=0031666650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031666650&partnerID=8YFLogxK

U2 - 10.1016/S0028-3908(98)00081-1

DO - 10.1016/S0028-3908(98)00081-1

M3 - Article

C2 - 9833635

AN - SCOPUS:0031666650

VL - 37

SP - 1063

EP - 1070

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 8

ER -